Laser therapy for immune disorders in Raynaud’s disease
https://doi.org/10.37895/2071-8004-2019-23-4-9-15
Abstract
Purpose. To study the effectiveness of intravenous laser blood irradiation (ILBI) for the correction of immune disorders in Raynaud’s disease. Material and methods. The researchers evaluated outcomes of examination and management of 57 patients with Raynaud’s disease. 40 (70.2%) women and 17 (29.8%) men. The angiospastic stage was registered in 7 patients, the angioparalytic stage - in 31 and the stage of trophic disorders - in 19. All patients had conservative therapy. Immunostimulating drugs were not prescribed. Ultrasound Dopplerography and duplex scanning were used to study blood circulation in hands. To assess the immune status, the following parameters of cellular chain - (CD3 (T-rosettes), CD4 (T-helpers), CD8 (T-suppressors), CD20 (B-lymphocytes), CD95 (apoptosis), CD16 (NK-cells), CD71 ( proliferation receptor) and CD32 (phagocytosis) - as well as the humoral chain (serum immunoglobulins LgA, IgM, IgG) were tested. For the immunocorrection, ILBI technique was applied with laser device Mustang-2000 (Russia): wavelength - 0.63 μm, radiation frequency 80 Hz, power - 2.0 mW, exposure - 20 min, course - 10 daily sessions. Results. All patients with Raynaud’s disease prior to ILBI had the established significant decrease in blood flow in the arteries of their hands, dysfunction of cellular and humoral chains of the immune system, in particular: suppression of all types of T-lymphocytes; decrease of serum immunoglobulins of class A and increase in immunoglobulins of class M in blood. After 10 ILBI sessions, one could observe normalized parameters of both cellular and humoral chains of the immunity. Conclusion. ILBI with low-level laser therapy as a part of complex treatment normalizes immune system, improves microcirculation in hands as well as leads to the regression of main symptoms of Raynaud’s disease.
About the Authors
D. A. Rakhmonov
Republican Scientific Center of Cardiovascular Surgery
Tajikistan
Dushanbe
Tajikistan
Dushanbe
D. D. Sultanov
Republican Scientific Center of Cardiovascular Surgery
Tajikistan
Dushanbe
Tajikistan
Dushanbe
N. T. Gulmuradov
Republican Scientific Center of Cardiovascular Surgery
Tajikistan
Dushanbe
Tajikistan
Dushanbe
O. Nematzoda
Republican Scientific Center of Cardiovascular Surgery
Tajikistan
Dushanbe
Tajikistan
Dushanbe
D. M. Konunova
Republican Scientific Center of Cardiovascular Surgery
Tajikistan
Dushanbe
Tajikistan
Dushanbe
F. D. Saydaliev
Republican Scientific Center of Cardiovascular Surgery
Tajikistan
Dushanbe
Tajikistan
Dushanbe
References
1. Geynitz A.V., Moskvin S.V. New technologies of intravenous laser blood irradiation: “VLOK+UFOK” and “VLOK-405”. M.–Tver: Triada, 2010: 96. [In Russ.].
2. Geynitz A.V., Moskvin S.V., Azizov G.A. Intravenous laser blood irradiation. Tver: Triada, 2006: 250. [In Russ.].
3. Gerasimova M.M., Cherdyntsev M.G. Clinical and immunological aspects of peripheral nervous system lesions in Raynaud’s phenomenon. Nevrologichasky bulleten. 2004; 36 (3–4): 26–29. [In Russ.].
4. Guseva N.G. Hands – a mirror of Raynaud’s phenomenon. Revmatologia. 2005; 7 (2): 27–29. [In Russ.].
5. Kalmykov E.L., Sadriev O.N. Nonspecific aorto-arteritis (Takayasu disease). Nauka molodykh (Eruditio Juvenium). 2015; 4: 127–133. [In Russ.].
6. Kononova D.M., Sadriev O.N. Comparative evaluation of open and thoracoscopic selective cervical-thoracic sympathectomy in Raynaud’s disease. Nauka molodykh. 2016; 2: 60–68. [In Russ.].
7. Kononovа D.M., Sultanov D.D., Gaibov A.D. et al. Comprehensive diagnostics and modern principles of the treatment of Raynaud’s disease. Vestnik pedagogicheskogo universiteta. 2015; 2–2 (63): 111–115. [In Russ.].
8. Ponomarenko G.N., Kutin Yu.S. Physiotherapy in patients with Raynaud’s disease. Fizioterapevt. 2010; 1: 49–50. [In Russ.].
9. Sultanov D.D., Tukhtaev F.M., Kurbanov N.R. et al. The syndrome of upper thoracic aperture. Vestnik Avicenni. 2014; 3 (60): 121–127. [In Russ.].
10. Sultanov D.D., Usmanov N.U., Gaibov A.D. The clinical picture and diagnostics of chronic upper limb ischemia. Angiologia i sosudistaya khirurgia. 1998; 4 (2): 29–35. [In Russ.].
11. Tabeeva G.R. Neurological aspects of Raynaud’s phenomenon. Consilium Medicum. 2002; 4 (8): 438–442. [In Russ.].
12. Tabeeva G.R., Glazychev O.S., Fokina N.M. et al. Optimization of Raynaud’s disease treatment. Consilium Medicum. 2007; 9 (8): 57–60. [In Russ.].
13. Shilova L.N., Chernov A.S., Trubenko Yu.A. et al. Raynaud’s Syndrome: clinical and immunological features in different variants. Fundamentalnie issledovania. 2015; 1: 1712–1716. [In Russ.].
14. Shipilova V.A. The Raynaud’s syndrome attack. Consilium Provisorum. 2007; 5 (4): 54–55. [In Russ.].
15. Shostak N.A., Klimenko A.A. Systemic vasculitis: new in classifi diagnostics and treatment. Klinitzist. 2015; 9 (2): 8–12. [In Russ.].
16. Brown S. Diagnosis and management of patients with Raynaud’s phenomenon. Nurs Stand. 2012; 26 (46): 41–46.
17. Gayraud M. Raynaud’s phenomenon. Joint Bone Spine. 2007; 74 (1): e1–e8. Doi: 10.1016/j.jbspin.2006.07.002.
18. Herrick A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012; 8 (8): 469–479. Doi: 10.1038/nrrheum.2012.96.
19. Knapik-Kordecka M., Wysokinski W.E. Clinical spectrum of Raynaud’s phenomenon in patients referred to vascular clinic. Cardiovasc Surg. 2000; 8 (6): 457–462.
20. Pearson J.D. Normal endothelial cell function. Lupus. 2000; 9 (3): 183–188.
21. Smyth A.E., Bell A.L., Bruce I.N. et al. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud’s phenomenon. Ann Rheum Dis. 2000; 59 (3): 870–874.
22. Stewart M., Morling J.R. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database Syst. Rev. 2012; 11: 7:CD006687. Doi: 10.1002/14651858.CD006687.pub3.
23. Suter L.G., Murabito J.M., Felson D.T. et al. The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum. 2005; 52 (4): 1259–1263. Doi: 10.1002/art.20988.
24. Youakim S. The validity of Raynaud’s phenomenon symptoms in HAVS cases. Occupational Medicine. 2008; 58 (6): 431–435. Doi: 10.1093/occmed/kqn075.
25. Ziegler S., Brunner M., Eigenbauer E., Minar E. Long-term outcome of primary Raynaud’s phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand. J. Rheumatol. 2003; 32 (6): 343–347. Doi: 10.1080/03009740410005007.
Review
For citations:
Rakhmonov D.A., Sultanov D.D., Gulmuradov N.T., Nematzoda O., Konunova D.M., Saydaliev F.D. Laser therapy for immune disorders in Raynaud’s disease. Laser Medicine. 2019;23(4):9-15. (In Russ.) https://doi.org/10.37895/2071-8004-2019-23-4-9-15
Views:
764
Email this article 